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Systematic characterization of cancer genomes has
revealed a staggering number of diverse aberrations
that differ among individuals, such that the functional
importance and physiological impact of most tumor
genetic alterations remain poorly defined. We devel-
oped a computational framework that integrates
chromosomal copy number and gene expression
data for detecting aberrations that promote cancer
progression. We demonstrate the utility of this
framework using a melanoma data set. Our analysis
correctly identified known drivers of melanoma and
predicted multiple tumor dependencies. Two depen-
dencies, TBC1D16 and RAB27A, confirmed empiri-
cally, suggest that abnormal regulation of protein
trafficking contributes to proliferation in melanoma.
Together, these results demonstrate the ability of
integrative Bayesian approaches to identify candi-
date drivers with biological, and possibly thera-
peutic, importance in cancer.INTRODUCTION
Large-scale initiatives to map chromosomal aberrations, muta-
tions, and gene expression have revealed a highly complex
assortment of genetic and transcriptional changes within indi-
vidual tumors. For example, copy number aberrations (CNAs)
occur frequently in cancer due to genomic instability. Genomic
data have been collected for thousands of tumors at high reso-
lution using array comparative genomic hybridization (aCGH)
(Pinkel et al., 1998), high-density single-nucleotide polymor-
phism (SNP) microarrays (Beroukhim et al., 2010; Lin et al.,
2008), and massively parallel sequencing (Pleasance et al.,
2010). Although multiple new genes have been implicated in
cancer through sequencing and CNA analysis (Garraway et al.,
2005), these studies have also revealed enormous diversity in
genomic aberrations in tumors among individuals. Each tumor
is unique and typically harbors a large number of genetic lesions,Cof which only a few drive proliferation and metastasis. Thus,
identifying driver mutations (genetic changes that promote
cancer progression) and distinguishing them from passengers
(those with no selective advantage) has emerged as a major
challenge in the genomic characterization of cancer.
The most widely used approaches are based on the frequency
that an aberration occurs: if a mutation provides a fitness advan-
tage in a given tumor type, its persistencewill be favored, and it is
likely to be found in multiple tumors. For example, GISTIC iden-
tifies regions of the genome that are aberrant more often than
would be expected by chance and has been used to analyze
a number of cancers (Beroukhim et al., 2007, 2009; Lin et al.,
2008). However, there are limitations to analytical approaches
based on CNA data alone: CNA regions are typically large and
contain many genes, most of which are passengers that are
indistinguishable in copy number from the drivers. CNA data
have statistical power to detect only the most frequently recur-
ring drivers above the large number of unrelated chromosomal
aberrations that are typical in cancer. Finally, these approaches
rarely elucidate the functional importance or physiological
impact of the genetic alteration on the tumor. These limitations
highlight the need for new approaches that can integrate addi-
tional data to identify drivers of cancer. Gene expression is
readily available for many tumors, but how best to combine it
with information on CNA is not obvious.
We postulate that driver mutations coincide with a ‘‘genomic
footprint’’ in the form of a gene expression signature. We devel-
oped an algorithm that integrates chromosomal copy number
and gene expression data to find these signatures and identify
likely driver genes located in regions that are amplified or deleted
in tumors. Each potential driver gene is altered in some, but not
all, tumors and, when altered, is considered likely to play
a contributing role in tumorigenesis. Unique to our approach,
each driver is associated with a gene module, which is assumed
to be altered by the driver. We sometimes gain insight into the
likely role of a candidate driver based on the annotation of the
genes in the associated module. We demonstrate the utility of
our method using a data set (Lin et al., 2008) that includes paired
measurements of gene expression and copy number from 62
melanoma samples. Our analysis correctly identified known
drivers of melanoma and connected them to many of theirell 143, 1005–1017, December 10, 2010 ª2010 Elsevier Inc. 1005
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Figure 1. Modeling Assumptions
For all heat maps, each row represents a gene and each column represents a tumor sample.
(A) The same chromosome in different tumors; orange represents amplified regions. The box shows regions amplified in multiple tumors.
(B) An idealized signature in which the target genes are upregulated (red) when the DNA encoding the driver is amplified (orange).
(C) A driver may be overexpressed due to amplification of the DNA encoding it or due to the action of other factors. The target genes correlate with driver gene
expression (middle row), rather than driver copy number (top row).
(D) Data representing amplified region on chromosome 17. Heat maps of expression for 10 of 24 genes that passed initial expression filtering (Extended Exper-
imental Procedures).
Samples are ordered according to amplification status of the region (orange, amplified; blue, deleted). These genes are identical in their amplification status, and
though gene expression is correlated with amplification status to some degree, the expression of each gene is unique. It is these differences that facilitate the
identification of the driver. See also Extended Experimental Procedures, Figure S1, and Table S1.targets and biological functions. In addition, it predicted novel
melanoma tumor dependencies, two of which, TBC1D16 and
RAB27A, were confirmed experimentally. Both of these genes
are involved in the regulation of vesicular trafficking, which high-
lights this process as important for proliferation in melanoma.
RESULTS
The Genomic Signature of a Driver
We define a ‘‘driver mutation’’ to be a genetic alteration that
provides the tumor cell with a growth advantage during carcino-
genesis or tumor progression (Stratton et al., 2009). We
reasoned that driver mutations might leave a genomic ‘‘foot-
print’’ that can assist in distinguishing between driver and
passenger mutations based on the following assumptions: (1)
a driver mutation should occur in multiple tumors more often
than would be expected by chance (Figure 1A); (2) a driver
mutation may be associated (correlated) with the expression of
a group of genes that form a ‘‘module’’ (Figure 1B); (3) copy
number aberrations often influence the expression of genes in
the module via changes in expression of the driver (Figure 1C).
Driver mutations are frequently associated with the abnormal
regulation of processes such as proliferation, differentiation,
motility, and invasion. Given that many cancer phenotypes are
reflected in coordinated differences in the expression of multiple
genes (a module) (Golub et al., 1999; Segal et al., 2004), a driver1006 Cell 143, 1005–1017, December 10, 2010 ª2010 Elsevier Inc.mutation might be associated with a characteristic gene expres-
sion signature or other phenotypic output representing a group
of genes whose expression is modulated by the driver. In addi-
tion, CNAs do not typically alter the coding sequence of the
driver and so are expected to influence cellular phenotype via
changes in the driver’s expression. In consequence, changes
in expression of the driver are important, so approaches that
measure association between the expression of a candidate
driver (as opposed to its copy number) and that of the genes in
the corresponding module are likely to promote the identification
of drivers.
Gene expression is particularly useful for identifying candidate
drivers within large amplified or deleted regions of a chromo-
some: whereas genes located in a region of genomic copy
gain/loss are indistinguishable in copy number, expression
permits the ranking of genes based on howwell they correspond
with the phenotype (Figure 1D). CNA data aids in determining the
direction of influence, which cannot be derived based on corre-
lation in gene expression alone (Figure 3A). This permits an unbi-
ased approach for identifying candidate drivers from any func-
tional family, beyond transcription factors or signaling proteins.
A Bayesian Network-Based Algorithm
to Identify Driver Genes
We developed a computational algorithm, copy number and
expression in cancer (CONEXIC), that integrates matched copy
Figure 2. The Highest-Scoring Modulators Identi-
fied by CONEXIC
Gene names are color coded based on the role of the gene
in cancer. Ten genes have been previously identified as
oncogenes or tumor suppressors (blue); of these, two in
melanoma (brown). Column 3 represents chromosomal
location, orange represents amplification, and blue repre-
sents deletion. These genes were identified within regions
containing multiple genes, and the number of genes in
each aberrant region is listed in column 4. Column 5 lists
the p value for modulator validation in independent data
(for a full list, see Table S2 and Figure S3C). p values are
shown for the Johansson data set unless the modulator
was missing from this data set, and then p value from
the Hoek data set is shown. See also Extended Experi-
mental Procedures, Table S2, and Figure S3.number (amplifications and deletions) and gene expression
data from tumor samples to identify driver mutations and
the processes that they influence. CONEXIC is inspired by
Module Networks (Segal et al., 2003) but has been augmented
by a number of critical modifications that make it suitable for
identifying drivers (see Extended Experimental Procedures avail-
able online). CONEXIC uses a score-guided search to identify
the combination of modulators that best explains the behavior
of a gene expression module across tumor samples and
searches for those with the highest score within the amplified
or deleted regions (Extended Experimental Procedures and
Figure S1).
The resulting output is a ranked list of high-scoring modulators
that both correlate with differences in gene expression modules
across samples and are located in amplified or deleted regions in
a significant number of these samples. The fact that the modula-
tors are amplified or deleted indicates that they are likely to
control the expression of the genes in the corresponding
modules (see Figure 3). Because the modulators are amplified
or deleted in a significant number of tumors, it is reasonable to
assume that expression of the modulator (altered by copy
number) contributes a fitness advantage to the tumor. Therefore,
the modulators likely include genes whose alteration provides
a fitness advantage to the tumor.
Identifying Candidate Driver Genes in Melanoma
We applied the CONEXIC algorithm to paired gene expression
and CNA data from 62 cultured (long- and short-term) mela-Cell 143, 1005–10nomas (Lin et al., 2008). A list of candidate
drivers was generated using copy number data
available for 101 melanoma samples by
applying a modified version (Sanchez-Garcia
et al., 2010) of GISTIC (Beroukhim et al., 2007)
(see Table S1). Next, we integrated copy
number and gene expression data (available
for 62 tumors) to identify the most likely drivers
(Extended Experimental Procedures). Statistical
power is gained by integrating all data and by
combining statistical tests on thousands of
genes to support the selected modulators.
This resulted in the identification of 64 modula-tors that explain the behavior of 7869 genes. We consider the
top 30 scoringmodulators, presented in Figure 2, as likely drivers
(see Table S2 for the complete list).
Many Modulators Are Involved in Pathways Related
to Melanoma
The top 30 modulators (likely drivers) include 10 known
oncogenes and tumor suppressors (Figure 2). In many cases,
CONEXIC chose the cancer-related gene out of a large aberrant
region containing many genes. For example, DIXDC1, a gene
known to be involved in the induction of colon cancer (Wang
et al., 2009b), was selected among 17 genes in an aberrant
region (Figure S2). CCNB2, a cell-cycle regulator, was selected
from a large amplified region containing 33 genes. The modula-
tors span diverse functional classes, including signal trans-
ducers (TRAF3), transcription factors (KLF6), translation factors
(EIF5), and genes involved in vesicular trafficking (RAB27A).
Performing a comprehensive literature search for all genes
is tedious and time consuming, so we developed an automated
procedure, literature vector analysis (LitVAn), which searches
for overrepresented terms in papers associated with genes
in a gene set. LitVAn uses a manually curated database (NCBI
Gene) to connect genes with terms from the complete text of
more than 70,000 published scientific articles (Extended Exper-
imental Procedures). LitVAN found a number of overrepresented
terms (Figure S3E) among the top 30 modulators, including
‘‘PI3K’’ and ‘‘MAPK,’’ which are known to be activated in mela-
noma; ‘‘cyclin,’’ representing proliferation, which is common in17, December 10, 2010 ª2010 Elsevier Inc. 1007
all cancers; and ‘‘RAB.’’ Rabs regulate vesicular trafficking, a
process not previously implicated in melanoma.
The Association between a Modulator and the Genes
in a Module
Beyond generating a list of likely drivers (modulators), the
CONEXIC output includes groups of genes that are associated
with each modulator (modules). We tested how reproducible
the modulators and their associated modules are using gene
expression data from two other melanoma cohorts with 45
(Hoek et al., 2006) and 63 (Johansson et al., 2007) samples
(see Extended Experimental Procedures and Figure S3). We
found that 51 of 64 (80%) of the selected modulators are
conserved across data sets in a statistically significant manner.
Modules (statistically associated genes) are likely enriched with
genes whose expression is biologically affected by the modu-
lator (Figure 3). In consequence, the processes and pathways
represented by genes in a module can help us to gain insight
into how an aberration in the modulator might alter the cellular
physiology and contribute to the malignant phenotype.
Annotation of data-derived sets of genes is typically carried out
basedongene set enrichment usingGeneOntology (GO) annota-
tion.Although this approach is useful, therearemodules forwhich
GOannotationdoes not capture the knownbiology. For example,
the ‘‘TNFmodule’’ is enrichedwith theGO terms ‘‘developmental
process’’ and ‘‘cell differentiation’’ (q value = 0.0014 and 0.004,
respectively). We used LitVAn to carry out a systematic literature
search and found 11 of 20 genes in the module related to the
TNF pathway, inflammation, or both (Figure 3C and Table S3),
although only two of these genes were annotated for these
processes in GO. TRAF3, the modulator chosen by CONEXIC, is
known to regulate the NF-kB pathway (Vallabhapurapu et al.,
2008), a major downstream target of TNF. Although TRAF3 has
not been previously implicated in melanoma, the importance of
the NF-kB pathway in melanoma is well supported (Chin et al.,
2006).
A Known Driver, MITF, Is Correctly Associated
with Target Genes
CONEXIC identified microphthalmia-associated transcription
factor (MITF) as the highest-scoring modulator. MITF is a master
regulator of melanocyte development, function, and survival
(Levy et al., 2006; Steingrı´msson et al., 2004), and the overex-
pression of MITF is known to have an adverse effect on patient
survival (Garraway et al., 2005).
To test theassociationbetweenmodulator andmodule,weob-
tained an experimentally derived list of MITF targets (Hoek et al.,
2008b) and asked whether the modules identified by CONEXIC
associate MITF with its known targets. The MITF-associated
modules contained 45 of 80 previously identified targets
(p value<1.531045) supporting amatchbetween the transcrip-
tion factor (TF) and its known targets. However, a few targets
(TBC1D16, ZFP106, and RAB27A) are both associated with
MITF and are themselves modulators of additional modules.
CONEXIC limits each gene to a single module, so association
with an MITF target would preclude association with MITF. If we
permit indirect association to MITF through the modules of
these additional modulators, CONEXIC correctly identifies 76 of1008 Cell 143, 1005–1017, December 10, 2010 ª2010 Elsevier Inc.the 80 targets identified by Hoek et al. (p value < 1.5 3 1078).
Similar target sets are not available for any other modulator,
precluding a more rigorous evaluation of our other predictions.
MITF Expression Correlates with Targets Better
Than Copy Number
Expression of MITF correlates with the expression of its targets
better than MITF copy number, though both correlations are
statistically significant (p value of 0.0001 versus 0.04; Figures 4A
and 4B). This relationship is unidirectional: MITF is significantly
overexpressed when its DNA is amplified (p value 0.0004), but
overexpressed MITF does not always correspond with MITF
amplification. We find that MITF is less correlated with its copy
number (rank 294th) than most other genes in aberrant regions
(see Table S1C), and more than half of the tumors that overex-
pressMITFdonot haveaCNAthat spans theMITFgene.Compar-
ison ofMITF target expression between sampleswith andwithout
MITF amplification did not show an effect of DNA amplification on
expression of the targets (Extended Experimental Procedures).
MITF Correctly Annotated with Its Known Role
in Melanoma
We used GO gene set enrichment to identify the biological
processes and pathways represented in each module associ-
ated with MITF. The module containing the genes most signifi-
cantly upregulated byMITF (Figure 4B and Figure S4A) is signif-
icantly enriched for the terms ‘‘melanosome’’ and ‘‘pigment
granule’’ (q value = 4.86e6 for each). It includes targets involved
in proliferation such as CDK2, consistent with the observation
that MITF can promote proliferation via lineage-specific regula-
tion of CDK2 (Du et al., 2004). The module containing genes
most strongly inhibited by MITF (Figure 4B and Figure S4B)
has a metastatic signature strongly associated with invasion,
angiogenesis, the extracellular matrix, and NF-kB signaling.
These modules and their annotation suggest that MITF serves
as a developmental switch between two types of melanoma, in
which high MITF expression promotes proliferation and low
MITF expression promotes invasion. Thus, our automated,
computationally derived findings dissect a complex response
and accurately recapitulate the known literature, including the
experimental characterization of MITF (Hoek et al., 2008a).
LitVAN annotated additional modulators with their known role
(e.g., CCNB2 with cell cycle and mitosis; data not shown). The
detailed match between the CONEXIC output and empirically
derived knowledge of the role of knownmodulators in melanoma
provides confidence in CONEXIC’s predictions for modulators
that are not well characterized.
Identification of TBC1D16 as a Tumor Dependency
in Melanoma
The second highest-scoring modulator identified by CONEXIC
is TBC1D16, a Rab GTPase-activating protein of unknown
biological function. Rabs are small monomeric GTPases
involved in membrane transport and trafficking. TBC1D16 is
well conserved, and although its targets are not known, a close
paralog, TBC1D15, regulates RAB7A (also selected as a modu-
lator; Figure 2) (Itoh et al., 2006). We used a module associated
with TBC1D16 to infer its potential role in melanoma (Figure 5A)
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Figure 3. Associating Modulators to Genes
(A) Three scenarios could explain a correlation between a candidate driver (gene A) and its target (gene B): A could influence B, B could influence A, or both could
be regulated by a common third mechanism (Pearl, 2000). The availability of both gene expression and chromosomal copy number data allows us to establish the
likely direction of influence. If the expression of gene A is correlated with its DNA copy number and the copy number is altered in a large number of tumors, it is
likely that the copy number alteration results in a change in expression of A in these tumors. So the model in which A influences the expression of B and other
correlated genes is the most likely. In this way, examination of both copy number and gene expression in a single integrated computational framework facilitates
identification of candidate drivers.
(B) Modulator influence on a module can go beyond direct transcriptional cascades involving transcription factors or signaling proteins and their targets. Genetic
alteration of any gene (e.g., a metabolic enzyme) can alter cell physiology, which is sensed by the cell and subsequently leads to a transcriptional response
through a cascade of indirect influences and mechanisms. Whereas modules are typically enriched for genes influenced by the modulator, they also contain
genes that are coexpressed with the modulator (‘‘joint modulator’’). Both types are helpful for annotating the module and determining the functional role of
the modulator.
(C) The TNF module. The modulators include TRAF3 andMITF, wherein high TRAF3 and lowMITF are required for upregulation of the genes in the module. The
annotation for each gene is represented in a color-codedmatrix. Blue and orange squares represent literature-based annotation (see Table S3); green and brown
are from GO. LitVAN associated the genes in this module with TNF and the inflammatory response.
See also Figure S2 and Table S3.
Cell 143, 1005–1017, December 10, 2010 ª2010 Elsevier Inc. 1009
C
MITF
Low Expression High Expression
Vesicular Trafficking
Melanogenesis
Lysosome/Endosome
Known MITF Targets
Genes overexpressed 
when MITF is high
are involved in:
NFkB/TNF
Invasion/Migration
Angiogenesis
Genes overexpressed 
when MITF is low
are involved in:
STX7, MYO5A, 
RAB27A, RAB7A, 
RAB38, SORT1, 
CDK2, MLANA, 
DCT...
SMAD3, CTGF, 
SMURF2, CCL2, 
NFKBIA, ITGA3, 
CXCL1, ITGA5...
76
 G
en
es
84
 G
en
es
Exp
CNA
MITF-ExpressionMITF-CNA
H
oe
k 
M
IT
F 
Ta
rg
et
s
BA
-2 20
Log Change
Expression:
CNA:
Deleted
Normal
Figure 4. MITF Expression Correlates with Expres-
sion of the Genes in the Associated Module
(A) Each row represents the gene expression of 1 of 78
MITF targets identified by Hoek (Hoek et al., 2008b); the
tumor samples are split into two groups based on the
copy number of MITF (Welch t test p value = 0.04).
(B) The rows represent the same genes, in the same order
as in (A), but here, the tumor samples are split into a group
of samples that expressMITF at high (n = 46) or low levels
(n = 16) (Welch t test p value = 0.0001).
(C) Two modules associated with MITF, showing a
selected subset of genes. LitVAN annotation for the genes
in each module is shown below the heat map. The com-
plete modules with all genes are available in Figure S4.and discovered that diverse biological processes are repre-
sented by genes in the module and that more than half are anno-
tated for processes such asmelanogenesis, vesicular trafficking,
and survival/proliferation (Table S4A). This suggests that
TBC1D16 plays a role in cell survival and proliferation.
TBC1D16 is an uncharacterized gene located in an amplified
region that contains 23 other genes, including CBX4, which is
known to play a role in cancer (Satijn et al., 1997). Expression
of TBC1D16 is not highly correlated with TBC1D16 copy
number compared to other genes in the region (ranked 7th out
of 24) or to all candidate drivers (252th out of 428). Nevertheless,
TBC1D16 is the top-scoring gene in the region and the second
highest-scoring modulator, so it was selected for experimental
verification.
The module exhibits a dose-response relationship between
TBC1D16 expression and the expression of genes in the module
such that higher expression of TBC1D16 is correlatedwith higher
expression of genes in the module (correlation coefficient 0.76).1010 Cell 143, 1005–1017, December 10, 2010 ª2010 Elsevier Inc.We carried out western blotting and RT-PCR on
some of the short-term cultures (STCs) used to
generate the Lin data set and asked whether
the TBC1D16 transcript correlates with protein
levels. The results confirmed that the expression
of TBC1D16 corresponds well with the amount
of the 45 kD isoform of TBC1D16 (data not
shown). These results suggest that knockdown
of TBC1D16 expression in tumors that have
high levels of TBC1D16 will lead to a reduction
in proliferation.
TBC1D16 Is Required for Proliferation
To test whether TBC1D16 is required for prolif-
eration of melanoma cultures, we carried out
a knockdown experiment. We selected two
STCs with high levels of TBC1D16, WM1960
(16-fold higher expression than WM1346, DNA
not amplified) and WM1976 (34-fold higher
expression, amplified DNA) and control STCs,
WM262 and WM1346 that express TBC1D16
at a lower level. We used two shRNAs to knock
down TBC1D16 expression in each of the four
STCs and measured growth over 8 days
(Extended Experimental Procedures). RT-PCRwas used to confirm that the reduction in the amount of the
TBC1D16 transcript was similar for all of the STCs (Figure S5).
Knockdown of TBC1D16 expression reduced cell growth in
WM1960 and WM1976 to 16% and 40%, respectively, relative
to controls infected with GFP shRNA in the same STCs (Figures
5B–5D). This result is specific for cultures with high levels of
TBC1D16, as the controls, WM262 andWM1346, grow at similar
rates to cultures infected with shGFP (75%–90%). As predicted,
growth inhibition at day 8 is proportional to the amount of the
TBC1D16 transcript and is independent of TBC1D16 copy
number (Figures 5C and 5D). Taken together, these results
support CONEXIC’s prediction that TBC1D16 is required for
proliferation in melanomas that overexpress the gene.
RAB27A Identified and Experimentally Confirmed
as a Tumor Dependency
The TBC1D16 module contains a second modulator, RAB27A,
also known to be involved in vesicular trafficking (Figure 5A).
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Figure 5. TBC1D16 Is Necessary for Melanoma Growth
(A) A module associated with TBC1D16 and RAB27A. The genes in the module are involved in melanogenesis, survival/proliferation, lysosome, and protein traf-
ficking (see Table S4A for details).
(B) Representative growth curves for each of the four STCs infectedwith TBC1D16 shRNA. Each curve represents three technical replicates. RT-PCRwas used to
confirm that the reduction in the amount of the TBC1D16 transcript was similar for all of the STCs (Figure S5).
(C) Change in growth over time, relative to the number of cells plated, averaged over all replicates (Extended Experimental Procedures). Mean over three bio-
logical replicates 3 three technical replicates for each STC. See Figure S5 and Table S4B for additional replicates and hairpins.
(D) Growth inhibition at 8 days is directly proportional to the amount of the TBC1D16 transcript and is independent of the TBC1D16 copy number.RAB27A functions with RAB7A to control melanosome transport
and secretion. RAB7A localizes to early melanosomes, whereas
RAB27A is found in mature melanosomes (Jordens et al., 2006).
CONEXIC selected both RAB27A and RAB7A as modulators.
RAB27A is in an amplified region that did not pass the standard
GISTIC q value threshold for significance, and expression of
the gene is not highly correlated with RAB27A copy number
compared to other candidate drivers (323th out of 428). Never-
theless, CONEXIC identified it as the top-scoring modulator out
of the 33 genes in this region and ranked it 8th out of 64 modu-
lators, and it was therefore selected for empirical assessment.
To test the prediction that RAB27A is important for prolifera-
tion in tumors with high levels of RAB27A, we tested the effect
of shRNA knockdown of the RAB27A transcript on proliferation.
We chose two STCs in which the gene is highly expressed
WM1385 (28-fold higher expression compared with A375, DNACamplified) and WM1960 (38-fold higher expression, DNA not
amplified) and two controls that express RAB27A at a lower level
(A375 and WM1930). Western blots show that expression of
RAB27A correlates with expression of the cognate gene in these
cultures (data not shown).
Knockdown of RAB27A expression using shRNA was similar
for all cultures (Figure S6) but only reduced cell growth signifi-
cantly in the STCs that overexpress RAB27A (18% or 35% in
WM1385 or WM1960 relative to the same cultures infected
with GFP shRNA).RAB27A shRNA had less impact (growth rates
of 65%–80%) in the control STCs that have low RAB27A (Figures
6A and 6B). Growth inhibition at 6 days is correlated with the
amount of the RAB27A transcript and is independent of
RAB27A copy number (Figures 6B and 6C). Taken together,
these results support CONEXIC’s prediction that RAB27A is
a tumor dependency in melanomas that overexpress RAB27A.ell 143, 1005–1017, December 10, 2010 ª2010 Elsevier Inc. 1011
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Figure 6. RAB27A Is Necessary for Melanoma
Growth
(A) Representative growth curves for each of the four STCs
infected with RAB27A shRNA. Each curve represents
three technical replicates. RT-PCR was used to confirm
that the reduction in the amount of the RAB27A transcript
was similar in all of the STCs (Figure S6).
(B) Change in growth over time, relative to the number of
cells plated, averaged over all replicates. Knockdown of
RAB27A expression in cells that express this gene at
high levels reduces proliferation. Data averaged over three
biological replicates 3 three technical replicates for each
STC. See Figure S6 and Table S5 for all data.
(C) Growth inhibition at 6 days is dependent on the amount
of the RAB27A transcript and is independent of RAB27A
copy number.RAB27A Affects the Expression of Genes
in Associated Modules
To test whetherRAB27A affects the expression of genes in asso-
ciated modules, as predicted by CONEXIC, we carried out
microarray profiling after knockdown of RAB27A in the test
STCs (WM1385 and WM1960). We compared the expression
profile after RAB27A knockdown to a control profile generated
by infecting the same STC with GFP shRNA. We used gene set
enrichment analysis (GSEA) (Subramanian et al., 2005) to test
whether each of the three modules associated with RAB27A
are enriched with genes that are differentially expressed (DEG)
after knockdown (see Extended Experimental Procedures). We
found that all three RAB27A-associated modules are signifi-
cantly enriched for genes affected by RAB27A (p values < 105
for all three modules; see Figure 7C) and that these modules
responded in the direction predicted by CONEXIC.
These results support our computational prediction that the
expression of RAB27A affects the expression of the genes in
the associated modules. We note that RAB27A functions as a
vesicular trafficking protein, suggesting that it influences gene
expression through an unknown and likely indirect mechanism.1012 Cell 143, 1005–1017, December 10, 2010 ª2010 Elsevier Inc.We used LitVAN to identify the biological
processes and pathways represented among
the DEGs. Cell cycle-related terms are signifi-
cant among the downregulated genes, which
might be expected given the reduced growth
afterRAB27A knockdown. In addition, we found
that genes annotated for the ERK pathway
are upregulated (including MYC, FOSL1, and
DUSP6). We usedGSEA tomeasure enrichment
of an experimentally derived set of genes that
respond to MEK inhibition in melanoma (Pratilas
et al., 2009). The resulting p value < 4.7 3 105
suggests that ERK signaling is altered after
RAB27A knockdown in these STCs.
TBC1D16 Influences the Expression
of Genes in Associated Modules
We carried out microarray profiling after knock-
down of TBC1D16 to evaluate whether expres-sion of TBC1D16 affects the expression of genes in the four
modules associated with it. We used two shRNAs to knock
down TBC1D16 in the test STCs (WM1960 and WM1976) and
compared the gene expression to controls infected with GFP
shRNA (in the same STCs). GSEA analysis established that all
four modules are significantly enriched for genes affected by
differences in TBC1D16 expression (p values < 105, 0.0002,
0.008, and 0.009, respectively; see Figure 7). Two modules
responded to TBC1D16 knockdown in the direction predicted
by CONEXIC. In addition, GSEA analysis ranked genes in
the TBC1D16 module (Module 25) highest out of 177 (based
on the GSEA p value), demonstrating that the genes in this
module are the most highly differentially expressed genes in
the data set.
The function of TBC1D16 is unknown, but it is predicted to be
involved in vesicular trafficking. In our knockdown analysis,
LitVAN annotated the upregulated genes with terms related to
vesicular trafficking. These include RAB3C, RAB7A, CHMP1B,
RAB18, SNX16, COPB1, and CAV1 (see Table S6A). However,
it is not clear how TBC1D16 affects gene expression or how
changes in expression affect vesicular trafficking.
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Figure 7. Results of Knockdown Microarrays for
RAB27A and TBC1D16
(A) To the left is one of the modules associated with
RAB27A, and to the right are data generated following
knockdown (KD) of RAB27A for the same genes in the
STCs indicated (pink and blue). The expression of genes
in the module goes down relative to shGFP, as predicted.
KD expression heat map shows Z scores (see Extended
Experimental Procedures) showing that these are some
of the most differentially expressed genes (DEGs) in the
genome.
(B) To the left is one of the modules associated with
TBC1D16, and to the right are data generated following
KD of TBC1D16 in the STCs indicated. The expression
of genes in the module goes up relative to shGFP, as
predicted. The test STCs (blue) and control STCs (pink)
respond differently, demonstrating the importance of
context (TBC1D16 overexpression status) in determining
the response.
(C) GSEA p value and ranking (relative to 177 CONEXIC
modules) forRAB27A- and TBC1D16-associatedmodules
(see Figure S7 for data). GSEA was calculated using the
median of four profiles (two cell lines 3 two hairpins) on
the test STCs. Significant p values indicate that knock-
down of RAB27A and TBC1D16 each affects the subset
of genes predicted by CONEXIC (note that 105 is the
smallest p value possible given that 100,000 permutations
are used). The color of the module name represents the
predicted direction of response to knockdown (red and
green represent up- and downregulated, respectively).
The arrow represents the observed response to knock-
down. The direction of response was correctly predicted
for two of four TBC1D16 modules and for all RAB27A
modules.
See also Figure S7 and Table S6.DISCUSSION
We have demonstrated that combining tumor gene expression
and copy number data into a single framework increases our
ability to identify likely drivers in cancer and the processes
affected by them. Gene expression allows us to distinguish
between multiple genes in an amplified or deleted region
(many of which are indistinguishable based on copy number)Cell 143, 1005–10and to identify those that are likely to be drivers.
The combination of data types allows us to iden-
tify regions that would be overlooked using
methods based on DNA copy number alone.
Expression of a Driver, Not Its Copy
Number, Drives Phenotype
The novelty of our method and the key to its
success is our modeling paradigm: the expres-
sion of a driver should correspond with the
expression of genes in an associated module.
Examination of MITF and its targets supports
our assumptions. Expression of MITF best
correlates with the expression of its targets,
but MITF overexpression does not always
correspond with MITF amplification. A changein DNA copy number is only one of many ways that gene expres-
sion can be altered. For example,MITF expression can be upre-
gulated via signaling from the Ras/Raf (oncogenic BRAF occurs
frequently inmelanoma) (Wellbrock et al., 2008) and Frizzled/Wnt
pathways (Chin et al., 2006).
Most methods for identifying drivers within aberrant regions
focus on genes whose expression is well correlated with the
copy number of the cognate DNA (Lin et al., 2008; Turner17, December 10, 2010 ª2010 Elsevier Inc. 1013
et al., 2010). The expression of many of the predicted drivers
that we identify is poorly correlated with their copy number, rela-
tive to other genes in the region and to all other candidate
drivers MITF (294th), TBC1D16 (252th) and RAB27A (323th)
(see Table S1C). We believe that the discrepancies between
CNA and expression arise because there are multiple ways to
up- or downregulate a gene. For example, TBC1D16 and
RAB27A were both identified as transcriptional targets of MITF
(Chiaverini et al., 2008; Hoek et al., 2008b) and are therefore
upregulated whenMITF is overexpressed. Moreover, we postu-
late that many drivers are less correlated with their copy number
than passengers due to selective pressure; if there is a fitness
advantage to up- or downregulate expression, the tumor will
find a mechanism to do so.
TBC1D16 and RAB27A Are Required for Proliferation
We tested two drivers predicted by CONEXIC with knockdown
experiments and showed that tumors that express either
TBC1D16 or RAB27A at high levels are dependent on the corre-
sponding gene for growth. Our results demonstrate that these
dependencies are determined by expression of the gene (in
both cases), rather than DNA amplification status, further sup-
porting the assumptions underlying our approach. Thus, we
not only identify tumor dependencies, but also the tumors in
which these genes are crucial for proliferation. Identifying depen-
dencies that are critical for tumor survival is needed for drug-
targeted therapies; for example, FLT3 inhibitors in AML, which
have had successful phase II trials (Fischer et al., 2010). Our
approach is unbiased with respect to protein function and
does not incorporate prior knowledge, thus enabling the identifi-
cation of dependencies in genes involved with vesicular traf-
ficking. TBC1D16 and RAB27A validate the ability of our
approach to correctly identify tumor dependencies and the
genes that they affect.
Association between Modulator and Module
A key feature of our approach is that CONEXIC goes beyond
identifying drivers. By associating candidate drivers with gene
modules and annotating them using information from the litera-
ture, CONEXIC provides insight into the physiological roles of
drivers and associated genes. We used LitVAn to find biological
processes and pathways overrepresented in each module and
to associate drivers with functions, accurately identifying targets
of MITF and annotating the functions of known drivers (MITF,
CCBN2, and TRAF3).
The results of microarray profiling following knockdown
further support the association between modulator and module
and confirm our ability to identify genes affected by TBC1D16
and RAB27A. We successfully connected genes involved in
vesicular trafficking to their effects on gene expression, likely
through a cascade of indirect influences. In addition to profiling
the STCs that highly express each of these genes (test STCs),
we also profiled two lower-expressing STCs (control STCs),
in which the effect of knockdown is less detrimental to
growth. For TBC1D16, there is substantial overlap in the DEGs
in the test STCs (p value < 6.6 3 1022), but not in the DEGs
between control and test STCs (p value > 0.76). This reflects
the complexity of the transformed state and demonstrates that1014 Cell 143, 1005–1017, December 10, 2010 ª2010 Elsevier Inc.genetic context has a fundamental impact on the effect of
a perturbation.
Genes Involved in Trafficking Are Important
in Melanoma
Of the top 30 drivers selected by CONEXIC, three genes
(TBC1D16, RAB27A, and RAB7A) are known to be involved in
vesicular trafficking (Itoh et al., 2006; Jordens et al., 2006). All of
these genes are amplified (DNA) and highly expressed (RNA) in
multiple melanomas. There is increasing evidence that genes
controlling trafficking play a role inmelanoma. Germline variation
inGolgiphosphoprotein 3 (GOLPH3), a gene involved in vesicular
trafficking, is associatedwithmultiple cancers (Scott et al., 2009).
Our data identify two novel dependencies that are encoded
in somatic CNAs, demonstrate the dependency of melanoma
on TBC1D16 and RAB27A expression for proliferation, and high-
light the potential role of vesicular trafficking in this malignancy.
The role of vesicular trafficking in melanoma has yet to be
characterized. Vesicular trafficking regulates many receptor
tyrosine kinases (RTKs) both spatially and temporally and thus
determines both the duration and intensity of signaling (Ying
et al., 2010). For example, RAB7A is involved in the regulation
of ERK signaling (Taub et al., 2007), and ERK is known to play
an important role in melanoma (Chin et al., 2006). Tight control
of ERK expression could potentially be important in melanocytes
because of its influence on MITF: ERK is required for the activa-
tion of MITF, but high levels of ERK lead to MITF degradation
(Wellbrock et al., 2008). It is possible that recurrent aberrations
in vesicular trafficking genes might involve control of ERK
signaling intensity. This is further supported by the upregulation
of an ERK signature (Pratilas et al., 2009) following RAB27A
knockdown in our data (p value < 4.7 3 105).
CONEXIC and Other Approaches
CONEXIC differs from other methods in a number of ways. First,
it uses the gene expression of a candidate driver, rather than its
copy number, as a proxy to report on the status of the gene, e.g.,
two tumors that overexpress a driver are treated equivalently
even if there is amplification in the DNA of only one of them.
Second, it associates a candidate driver with a module of genes
whose expression corresponds with that of the predicted driver,
which was critical for identification of TBC1D16 as a modulator.
Third, combining copy number and gene expression provides
greater sensitivity for identifying significantly aberrant regions
that would not be selected based on DNA alone; this was critical
for the identification of RAB27A.
Methods based on copy number data are limited to detecting
large regions containing multiple genes, such that the driver
cannot be readily identified among them. Recent efforts have
focused on integrating additional sources of information into
the analysis. Some methods use prior information, such as the
role of a gene in other cancers (Beroukhim et al., 2010). Others,
like CONEXIC, integrate gene expression data (Adler et al.,
2006), but the results of these methods fall short of CONEXIC’s.
We systematically compared CONEXIC to other methods using
the same data and found that they did not identify MITF or any
other known driver in melanoma (see Extended Experimental
Procedures).
Statistical dependencies in gene expression have been used
to connect a regulator to its target (Friedman et al., 2000; Lee
et al., 2006; Segal et al., 2003) and for uncovering important
regulators in cancer (Adler et al., 2006; Carro et al., 2010;
Wang et al., 2009a). These approaches typically only detect tran-
scription factors and signaling molecules and do not connect the
altered regulatory networks to upstream genetic aberrations.
Incorporating information on amplification or deletion status
allows us to consider any functional class of genes and thus
permits detection of vesicular trafficking genes that would not
be identified using other methods. It also allows us to relate
the malignant phenotype to genetic aberrations from which it is
likely to have originated.
We tuned our method toward reducing the selection of modu-
lators that are not drivers. To gain this specificity, we do not
detect all genes and pathways that drive tumors. First, some
drivers in amplified and deleted regions do not pass the stringent
statistical tests employed in ourmethod. Second, CONEXIC only
identifies candidate drivers that are encoded in amplified or
deleted regions. In consequence, it would not detect drivers of
melanoma such asBRAF andNRAS that are typically associated
with point mutations. Third, CONEXIC detects drivers based on
the assumptions delineated above; though these hold for many
drivers, it is likely that they are not appropriate for all drivers.
To meet the challenge of finding all driving alterations in
cancer, a number of complementary approaches are needed.
Experimental approaches such as screening using pooled short
hairpin RNAs (shRNAs) (Bric et al., 2009; Zender et al., 2008) are
likely to detect a set of drivers different from those detected by
CONEXIC. These screens are dependent on the genetic back-
ground and are limited to drivers that influence processes that
can be readily measured, such as proliferation, whereas
CONEXIC scans all of the genetic data together and can poten-
tially identify drivers of any function across different genetic
backgrounds. In the future, we envision that CONEXIC will be
used to guide in vivo screening initiatives and to assist in the
choice of regions, functional assays, and genetic backgrounds
probed.
Beyond Melanoma
The challenge of finding candidate drivers is considerable:
tumors are heterogeneous, the data are noisy and highly corre-
lated, and there are a large number of possible combinations
of drivers and genes in modules. Our approach is successful
because it couples simple modeling assumptions with powerful
computational search techniques and rigorous statistical evalu-
ation of the results at each step.
Both the principles underlying CONEXIC and the software can
be applied to any tumor cohort containing matched data for
copy number aberrations and gene expression. The principle
of associating any type of mutation (e.g., epigenetic alterations
and coding sequence) with gene expression signatures or
other phenotypic outputs that differ among samples will be of
increasing importance as sequence and epigenetic data accu-
mulate. Not only does this help to distinguish between driver
and passenger mutations, but the genes in the associated
module can also provide insight into the role of the driver. This
approach can be used to identify the genetic aberrations respon-Csible for tumorigenesis and to find those that relate to any other
measurable phenotype, such as the resistance of tumors to
drugs. We anticipate that our approach will make an important
contribution toward a basic mechanistic understanding of
cancer and in revealing associations of clinical significance.
Cancer is a heterogeneous disease in which we are only just
beginning to appreciate the importance of genetic background
and the myriad ways in which the cellular machinery can be re-
directed toward the transformed state. Methods that begin to
dissect this complexity move us another step closer to a world
where personalized therapies are routine.
EXPERIMENTAL PROCEDURES
Statistical Methods
A detailed description of the statistical methods and computational algorithms
used can be found in the Extended Experimental Procedures. The CONEXIC
and LitVAN algorithms were developed for this research, and the software is
available at http://www.c2b2.columbia.edu/danapeerlab/html/software.html.
Experimental Methods
Cells were grown using standard culture conditions, and knockdown was
carried out by infection with lentivirus using RNAi sequences designed by
the RNAi Consortium. shRNA lentivirus were prepared according to TRC
protocols (http://www.broadinstitute.org/rnai/trc), with minor modifications.
Cell proliferation assays, RT-PCR, microarrays, and immunoblotting were
carried out using standard techniques. Primer sequences and detailed
methods can be found in the Extended Experimental Procedures.
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All primary data are available at the Gene Expression Omnibus (GSE23884).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, eight
figures, and six tables and can be found with this article online at doi:10.1016/
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